Trial Profile
An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin Following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients With Advanced Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Pharmacokinetics, safety and drug-drug interaction results (n=15) were presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 15 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.